

Barcelona, 18<sup>th</sup> November 2022

## **OTHER RELEVANT INFORMATION**

### **Almirall perpetually licenses Motilex<sup>®</sup> to Teofarma in Italy**

In accordance with Securities Markets Law Almirall, S.A. (“Almirall”) announce the following:

Almirall S.A. perpetually licenses Motilex<sup>®</sup> (Clebopride) to Teofarma in Italy. The agreement between Teofarma and Almirall includes Italian rights for Motilex<sup>®</sup> 0.5 mg tablets.

Motilex<sup>®</sup> (Clebopride) is indicated to treat adults and children for the relief of the symptoms of nausea and vomiting.

Sincerely,

Pablo Divasson del Fraile  
Investor Relations Department  
[investors@almirall.com](mailto:investors@almirall.com)